

Revence appoints Tobin C. Schilke as CFO

11 October 2018 | News

Schilke is a proven leader in the global biopharma arena, with 20 years of experience. He joins Revence from Achaogen, where he was chief financial officer since 2016. While at Achaogen, he raised more than \$300 million in capital and built out Achaogen's teams and capabilities in financial planning and analysis (FP&A), accounting, procurement, IT and facilities management.



Singapore – Revence Therapeutics, a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, announced that it has strengthened its leadership team with the appointment of Tobin C. Schilke as chief financial officer, effective November 5th. Schilke will report to Dan Browne, president and chief executive officer.

“Toby is a great steward of financial integrity, bringing significant value and global business insights. He has raised capital, completed mergers and acquisitions (M&A) and led operating finance organizations to support commercial activities for global biopharma businesses. We are thrilled to add Toby to our executive team, as we focus on our regulatory filings in the U.S. and internationally and enter our next critical phase of growth,” said President and Chief Executive Officer Dan Browne. “Toby is analytical, has a strong work ethic and possesses the financial and technical experience to help us accomplish our goals.”

Schilke is a proven leader in the global biopharma arena, with 20 years of experience. He joins Revence from Achaogen, where he was chief financial officer since 2016. While at Achaogen, he raised more than \$300 million in capital and built out Achaogen's teams and capabilities in financial planning and analysis (FP&A), accounting, procurement, IT and facilities

management. Prior to Achaogen, he spent 13 years at Roche/Genentech in a variety of senior finance and operational roles including CFO of Roche Products Limited in the United Kingdom, director of commercial FP&A for Genentech's BioOncology business, and M&A project manager for a number of successful acquisition, spin-out and business development deals for Roche.

Schilke holds a Master of Business Administration from Cornell University, a Master of Science in Chemical Engineering from University of California, Berkeley and a Bachelor of Science in Chemical Engineering from Lafayette College.